Rheumatoid disorders ranging from Rheumatoid Arthritis (RA) and Psoriatic Arthritis (PsA) to ankylosing spondylitis (AS) have seen huge therapeutic advancements over the last decade.
From the release of the groundbreaking anti-TNF products, through to the arrival of new biologic agents including interleukin inhibitors, JAK inhibitors and anti-TKY-2 inhibitors, patient experience has been significantly improved. These advancements have provided ever increasing convenience, efficacy and tolerability.
However, diagnostic and predictive biomarkers remain one area within the rheumatoid conditions that have seen limited commercial development in recent years. Late diagnosis and unpredictability of patient response to biologic treatment remains a major unmet need within rheumatoid disorder causing both underdiagnosis and repeated treatment failures in patients.
A number of diagnostic biomarkers currently show promise for RA, and predictive biomarkers hold huge potential, particularly in PsA. This article will look to explore a number of different biomarkers currently under investigation and the potential influence this will have for pharmaceutical companies working within the space.
Take a look at our whitepaper which explores a number of different biomarkers currently under investigation and the potential influence this will have for pharmaceutical companies working within the space.